Format

Send to

Choose Destination
Bioorg Med Chem. 2015 Jun 1;23(11):2699-715. doi: 10.1016/j.bmc.2014.12.021. Epub 2014 Dec 20.

MCR synthesis of a tetracyclic tetrazole scaffold.

Author information

1
Department of Drug Design, University of Groningen, A. Deusinglaan 1, Groningen 9700 AD, The Netherlands.
2
Carmolex Inc., Pittsburgh, USA.
3
Technische Universität München, Germany.
4
Department of Drug Design, University of Groningen, A. Deusinglaan 1, Groningen 9700 AD, The Netherlands. Electronic address: a.s.s.domling@rug.nl.

Abstract

Scaffold diversity is key in the ongoing exercise of discovery of novel bioactive compounds using high throughput screening (HTS). Based on the Ugi tetrazole synthesis we have designed novel bi- and tri-cyclic scaffolds featuring interesting pharmacophore properties. The compounds of the scaffold (B) are synthesizable in large diversity and numbers in two steps using (hetero)phenylethylamines, HN3, oxo components and iscyanoacetaldehyde(dimethylacetale). The chemistry is amenable to parallel synthesis and is used to enhance and fill the screening decks of the European Lead factory (ELF). Here, we are reporting full experimental details, scope and limitations of the reaction, cheminformatic analysis and the 3D structures of selected compounds.

KEYWORDS:

Isocyanide; Parallel; Pictet–Spengler; Synthesis; Tetrazol; Ugi

PMID:
25630499
PMCID:
PMC4733496
DOI:
10.1016/j.bmc.2014.12.021
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center